JP:4591 Stock Latest News
Company AnnouncementsRibomic Signs Foreign DDS Aptamer Evaluation Deal, Updates FY 2027 Outlook2w ago4591
Company AnnouncementsRibomic Reports Sustained Growth Benefits in Interim Phase 2 Data for Achondroplasia Drug1M ago4591- Company AnnouncementsRIBOMIC Reports Early Safety Data for Umedaptanib Pegol in Achondroplasia Study1M ago4591
Company AnnouncementsRibomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan2M ago4591
Company AnnouncementsRibomic Posts Quarterly Loss but Maintains Strong Equity Base and Full-Year Outlook2M ago4591
Company AnnouncementsRIBOMIC Begins Phase 3 Trial of Orphan Drug Umedaptanib Pegol for Paediatric Achondroplasia4M ago4591Company AnnouncementsRibomic Widens Losses but Boosts Liquidity as It Projects Deeper Red Ink5M ago4591
Company AnnouncementsRIBOMIC Files IND for Phase III Trial of Achondroplasia Drug in Japan7M ago4591
Company AnnouncementsRibomic’s Achondroplasia Drug Hits Phase II Height-Growth Goal, Paving Way for Phase III8M ago4591
Company AnnouncementsRIBOMIC Posts Continued Losses but Maintains Strong Equity Base in Nine-Month Results8M ago4591
Company AnnouncementsRIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment11M ago4591
Company AnnouncementsRibomic Inc. Reports Six-Month Financial Results with No Revenues11M ago4591Company AnnouncementsRIBOMIC Reports Successful Phase II Trial for Achondroplasia Treatment1y ago4591
Company AnnouncementsRIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment1y ago4591
Company AnnouncementsRIBOMIC Discovers New Treatment Potential for Diabetic Retinopathy1y ago4591
Company AnnouncementsRIBOMIC Reports Sustained Efficacy of Umedaptanib Pegol in Achondroplasia Trial1y ago4591- Company AnnouncementsRibomic Inc. Reports Continued Losses in Q1 20251y ago4591
Company AnnouncementsRIBOMIC to Launch Phase III Trial for Achondroplasia Drug in 20261y ago4591
Company AnnouncementsRibomic Inc. Reports Continued Net Loss for Fiscal Year 20251y ago4591Company AnnouncementsRibomic Inc. Reports Improved Financial Results for Nine Months Ending December 20241y ago4591
